U.S. label record. The cited DailyMed label identifies Lixisenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Two selected trials address cardiovascular outcomes in type 2 diabetes and exploratory motor outcomes in early Parkinson disease. These are lixisenatide trials, not evidence for the insulin-glargine combination as an interchangeable intervention.↗↗
What the reviewed sources report
ELIXA met cardiovascular noninferiority but did not demonstrate cardiovascular superiority. A smaller Parkinson trial reported less motor-score worsening over 12 months, with gastrointestinal adverse effects; it does not establish neuroprotection or a new approved indication.↗↗
What remains unresolved?
How do the monotherapy and fixed-combination regulatory records differ?↗↗
What do the broader diabetes program and subsequent Parkinson trials establish?↗↗
This single-ingredient label covers glycemic control alongside diet and exercise in adults with type 2 diabetes. It is separate from the insulin glargine/lixisenatide combination label cited by the profile, and does not establish current commercial availability. Label: 1 ↗
Which safety limits matter?
The label contraindicates severe hypersensitivity and addresses anaphylaxis, pancreatitis, hypoglycemia with insulin or insulin secretagogues, acute kidney injury, immunogenicity, gallbladder disease and aspiration during anesthesia or deep sedation. It does not recommend use in gastroparesis. Label: 4, 5, 6 ↗
Label edition and source pins
FDA-hosted U.S. prescribing information. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
EMA’s November 2012 review found HbA1c improvements when lixisenatide was added to specified background therapies. Placebo-adjusted changes and changes from baseline differed, and results varied between trial populations. EMA PDF pp. 77, 79 ↗
More findings, study links and document coverage
A comparison did not robustly establish equivalence
EMA judged noninferiority to exenatide on glycemic and weight outcomes not robustly demonstrated. A favorable overall regulatory decision did not mean every comparative endpoint was established. EMA PDF pp. 79 ↗
Safety interpretation needs the background regimen
The review identifies gastrointestinal symptoms, injection-site and allergic reactions, with hypoglycemia principally alongside insulin or sulfonylureas. Evidence in people over 75 and those with substantial kidney impairment was limited. EMA PDF pp. 77, 78, 79 ↗
Keep the historical review separate from later status
ELIXA was still ongoing in this assessment. The downloaded PDF is now marked as a product no longer authorized, so its original favorable recommendation is not proof of current EU authorization or later cardiovascular benefit. EMA PDF pp. 1, 80 ↗
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
European medicine records · 2 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: lixisenatide. EMA record ↗
Authorisation withdrawal, expiry, revocation or lapse: 2025-12-18. EMA metadata last updated 2026-02-05. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Identity/name search without publication-type filtering; primary human reports, extensions, combinations and other reports require separate eligibility decisions. Known selected reports were recovered.
731 retrieved · 2 included · 0 excluded · 729 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"lixisenatide"[Title/Abstract] OR "Adlyxin"[Title/Abstract] OR "Lyxumia"[Title/Abstract] OR "AVE0010"[Title/Abstract]
Full-text appraisal and screening of unassessed records remain open.
Registry comparison, additional aliases and references, and regulator reconciliation require separate checks.
Showing 25 of 731 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 38598572 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT03439943.
PubMed 26630143 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT01147250.
PubMed 42473266 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42697752 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42692277 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42687799 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42556625 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42401410 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42387313 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42698423 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42609010 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 30000034 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42666495 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42584027 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42296503 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42259643 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42186210 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42025665 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41792979 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 40145958 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42536323 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42490867 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41994910 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 41444101 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
PubMed 42452511 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
2 retrieved · 2 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA BLA208673 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: INSULIN GLARGINE, LIXISENATIDE.
FDA BLA208471 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIXISENATIDE.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
2 retrieved · 2 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/004243 — include: EMA feed product Suliqua; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA EMEA/H/C/002445 — include: EMA feed product Lyxumia; reported status: Withdrawn. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
25 retrieved · 16 included · 0 excluded · 9 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 25 of 25 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 20482 — include: Document linked by EMA product number; content unappraised. Suliqua : EPAR - Public assessment report
EMA 30245 — include: Document linked by EMA product number; content unappraised. Suliqua : EPAR - All Authorised presentations
EMA 38350 — include: Document linked by EMA product number; content unappraised. Suliqua : EPAR - Medicine overview
EMA 46983 — include: Document linked by EMA product number; content unappraised. Suliqua-H-C-PSUSA-00010577-201905 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 47100 — include: Document linked by EMA product number; content unappraised. Suliqua-H-C-4243-II-0011: EPAR - Assessment Report- Variation
EMA 55983 — include: Document linked by EMA product number; content unappraised. Suliqua-H-C-PSUSA-00010577-202111 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
EMA 49818 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - Risk-management-plan summary
EMA 28007 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - Public assessment report
EMA 32330 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - All Authorised presentations
EMA 39362 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 64723 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - Procedural steps taken and scientific information after authorisation
EMA 13355 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - Summary for the public
EMA 41911 — include: Document linked by EMA product number; content unappraised. Suliqua : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 21962 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - Product Information
EMA 21301 — include: Document linked by EMA product number; content unappraised. Suliqua : EPAR - Product Information
EMA 74418 — include: Document linked by EMA product number; content unappraised. Suliqua : EPAR - Procedural steps taken and scientific information after authorisation
EMA 52578 — not screened: Title-name match awaiting identity and document review. P/0443/2020 : EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (Lyxumia) (EMEA-000916-PIP01-10-M07)
EMA 28652 — not screened: Title-name match awaiting identity and document review. P/18/2011: EMA decision of 24 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lixisenatide (EMEA-000916-PIP01-10) in accordance with...
EMA 43773 — not screened: Title-name match awaiting identity and document review. P/0380/2018: of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (Lyxumia), (EMEA-000916-PIP01-10-M06)
EMA 15493 — not screened: Title-name match awaiting identity and document review. P/0076/2012: EMA decision of 25 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (EMEA-
000916-PIP01-10-M02)
EMA 24408 — not screened: Title-name match awaiting identity and document review. P/0035/2013: EMA decision of 27 February 2013 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide, (EMEA-000916-PIP01-10-M03)
EMA 26848 — not screened: Title-name match awaiting identity and document review. P/225/2011: EMA decision of 27 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (EMEA-
000916-PIP01-10-M01)
EMA 29319 — not screened: Title-name match awaiting identity and document review. P/168/2010: European Medicines Agency decision of 3 September 2010 on the granting of a product specific waiver for lixisenatide / insulin glargine,
(EMEA-000915-PIP01-10)
EMA 41211 — not screened: Title-name match awaiting identity and document review. P/0037/2015: EMA decision of 6 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (Lyxumia) (EMEA-000916-PIP01-10-M04)
EMA 41987 — not screened: Title-name match awaiting identity and document review. P/0133/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (Lyxumia), (EMEA-000916-PIP01-10-M05)
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
77 retrieved · 0 included · 0 excluded · 77 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Lixisenatide" OR "Soliqua 100/33" OR "Suliqua" OR "Lyxumia"
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 25 of 77 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT01960179 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02276196 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02058160 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03798054 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03881995 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00931372 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00763451 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04196231 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07173712 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03819790 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02767596 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02501850 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01572649 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02713477 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01147250 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT07274644 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00715624 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01146678 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00763815 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT02168491 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03798080 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06716424 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05136287 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00707031 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00866658 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Read the full Human Evidence Review
Supervised synthesis
What do selected human studies report about Lixisenatide?
Two selected trials address cardiovascular outcomes in type 2 diabetes and exploratory motor outcomes in early Parkinson disease. These are lixisenatide trials, not evidence for the insulin-glargine combination as an interchangeable intervention.12
Bottom line from this bounded source set
ELIXA met cardiovascular noninferiority but did not demonstrate cardiovascular superiority. A smaller Parkinson trial reported less motor-score worsening over 12 months, with gastrointestinal adverse effects; it does not establish neuroprotection or a new approved indication.12
Reviewed study record
ELIXA: cardiovascular outcomes
Design
Randomized placebo-controlled trial added lixisenatide or placebo to usual care.1
Population
6,068 people with type 2 diabetes and a recent acute coronary event were followed for a median of 25 months.1
Outcomes reported
The primary cardiovascular composite occurred in 13.4% versus 13.2%; hazard ratio 1.02 (95% CI 0.89–1.17). Noninferiority was met, superiority was not. Serious adverse events were not more frequent with lixisenatide.1
Limitations
The result is a cardiovascular safety comparison in a high-risk population, not evidence of cardiovascular benefit or the entire glycemic-efficacy program.1
Reviewed study record
LIXIPARK: exploratory Parkinson trial
Design
Randomized, double-blind, placebo-controlled phase 2 trial with 12 months of treatment and a two-month washout.2
Population
156 people with early Parkinson disease were randomized while receiving stable symptomatic therapy.2
Outcomes reported
The between-group difference in motor-score change at 12 months was 3.08 points favoring lixisenatide. Nausea occurred in 46% and vomiting in 13% of active-group participants.2
Limitations
The primary assessment was in the on-medication state. A small phase 2 study cannot establish disease modification, long-term benefit or safety; larger trials are required.2
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa1509225. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2312323. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Lixisenatide?
U.S. label record. The cited DailyMed label identifies Lixisenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
A phase value is unavailable here for 4 selected records; this is not counted as “no phase.”
A status value is unavailable here for 4 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
14 of 34 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Publication typesJournal Article 11Research Support, Non-U.S. Gov't 5Comment 3Letter 3Clinical Trial, Phase II 1Clinical Trial, Phase III 1Comparative Study 1Network Meta-Analysis 1Randomized Controlled Trial 1Review 1Systematic Review 1
Bibliography fields unavailable here for 20 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
1
FDA Federal Register documents
3
DailyMed SPL versions
20
Canonical profile
Published
Profile structured data
Published
Linked dated records
64
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
PeptideScanner retained ClinicalTrials.gov record NCT02745470 at 2026-07-30T21:22:00.254Z. Its registry update date was 2017-11-29, and PeptideScanner's reviewed identity mapping was lixisenatide.
DailyMed lists Structured Product Labeling version 1 for the reviewed Lixisenatide label family with a published date of 2016-11-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.
Evidence summary
What the cited records say
The cited DailyMed label identifies Lixisenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
PeptideScanner retained PubMed bibliographic metadata for PMID 39604042 at 2026-07-30T16:31:16.748Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2024-11-27. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38870730 at 2026-08-10T18:13:32.367Z. PubMed recorded a metadata revision date of 2026-07-02 and an Entrez history date of 2024-06-13. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38685598 at 2026-07-30T16:14:06.932Z. PubMed recorded a metadata revision date of 2026-06-18 and an Entrez history date of 2024-04-30. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38877681 at 2026-07-30T16:20:38.897Z. PubMed recorded a metadata revision date of 2026-05-31 and an Entrez history date of 2024-06-15. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 39407425 at 2026-07-30T16:20:39.038Z. PubMed recorded a metadata revision date of 2026-05-31 and an Entrez history date of 2024-10-16. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 22564709 at 2026-07-30T16:20:34.419Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2012-05-09. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 39157869 at 2026-07-30T16:23:36.341Z. PubMed recorded a metadata revision date of 2026-03-23 and an Entrez history date of 2024-08-19. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
DailyMed lists Structured Product Labeling version 25 for the reviewed Lixisenatide label family with a published date of 2026-03-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41623754 at 2026-07-30T16:25:14.225Z. PubMed recorded a metadata revision date of 2026-02-04 and an Entrez history date of 2026-02-02. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 25012990 at 2026-07-30T16:30:52.644Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-07-12. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 25055456 at 2026-07-30T16:30:52.649Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-07-25. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 25115916 at 2026-07-30T16:30:52.653Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-08-14. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗